n our study population from Northeastern Brazil, the frequency of HLA-B*5701 was between Caucasian and African ethnic groups; however, when stratifying for ethnicity, our findings show that the HLA B*5701 carriers' frequencies are more similar to those previously reported for Caucasians and Africans. Considering the clinical importance of hypersensitivity to Abacavir treatment in HIV-infected patients and the frequency of HLA B*5701 carriers reported in this study (3.1% in patients and 3.4% in the controls), we suggest the preventive use of HLA B*5701 testing in clinical practice in Abacavir treatment in Northeastern Brazil.
Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil / Crovella, Sergio; Biller, L.; Santos, S.; Salustiano, A.; Brandao, L.; Guimaraes, R.; Segat, L.; J. L., De; Arraes, L. C.. - In: CLINICS. - ISSN 1807-5932. - STAMPA. - 66:(2011), pp. 1485-1488. [10.1590/S1807-59322011000800030]
Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.
CROVELLA, SERGIO;L. Segat;
2011-01-01
Abstract
n our study population from Northeastern Brazil, the frequency of HLA-B*5701 was between Caucasian and African ethnic groups; however, when stratifying for ethnicity, our findings show that the HLA B*5701 carriers' frequencies are more similar to those previously reported for Caucasians and Africans. Considering the clinical importance of hypersensitivity to Abacavir treatment in HIV-infected patients and the frequency of HLA B*5701 carriers reported in this study (3.1% in patients and 3.4% in the controls), we suggest the preventive use of HLA B*5701 testing in clinical practice in Abacavir treatment in Northeastern Brazil.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
